Cellectricon

Cellectricon operates as a specialized neuroscience drug discovery services provider, leveraging a proprietary in vitro technology platform to offer end-to-end research solutions. The company has recently expanded its service portfolio with dedicated Neurotoxicity Testing modules and is actively forming strategic partnerships to strengthen its global presence, particularly in Japan. As a private, revenue-generating CRO, Cellectricon's business model is built on collaborative, fee-for-service engagements aimed at helping clients identify novel targets and compounds while assessing safety liabilities earlier in the R&D process.

Proprietary in vitro platform utilizing novel technologies, advanced readouts, and physiologically relevant biological systems (including microfluidic co-culture models) for neuroscience target discovery, lead optimization, and neurotoxicity testing.

Cellectricon competes with large, global full-service CROs (e.g., Charles River, Labcorp) and specialized neuroscience/biotech boutiques offering discovery services. Its differentiation lies in its deep, exclusive focus on neuroscience, a proprietary technology platform, and a highly collaborative, customized service model.